How big is the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market?

The Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size is expected to reach USD 3.94 billion in 2024 and grow at a CAGR of 5.90% to reach USD 5.25 billion by 2029. Read More

What is the current Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size?

In 2024, the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size is expected to reach USD 3.94 billion. Read More

Who are the key players in Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market?

Novo Nordisk, AstraZeneca, Eli lilly and Company, Sanofi and Pfizer are the major companies operating in the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market. Read More

What years does this Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market cover, and what was the market size in 2023?

In 2023, the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size was estimated at USD 3.72 billion. The report covers the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Share

Statistics for the 2023 & 2024 Europe Glucagon-Like Peptide-1 (GLP-1) Agonists market share, created by Mordor Intelligence™ Industry Reports. Europe Glucagon-Like Peptide-1 (GLP-1) Agonists share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Industry

The Europe GLP-1 market is consolidated, with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, AstraZeneca, etc., holding a presence in the region.